These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34996485)

  • 1. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.
    Kong H; Bai Q; Li A; Zhou X; Yang W
    Diagn Pathol; 2022 Jan; 17(1):5. PubMed ID: 34996485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
    PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
    Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
    JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
    Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
    Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
    Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
    Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
    Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
    Gordian-Arroyo AM; Zynger DL; Tozbikian GH
    Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
    Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FISH and HER2/
    Patil Okaly GV; Panwar D; Lingappa KB; Kumari P; Anand A; Kumar P; Chikkalingaiah MH; Kumar RV
    Indian J Cancer; 2019; 56(2):119-123. PubMed ID: 31062729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.